A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.

Background: FLT-PET/CT can accurately identify and locate functional bone marrow (FBM) with hematopoietic capability, the FBM were divided into two levels as FBM (strongest hemopoietic ability region)and FBM (moderate hemopoietic ability region) via FLT-PET/CT. The purpose of this study was to explore the relationship between dose-volume parameters of pelvic FBM and hematologic toxicity (HT) during radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.

Methods: From December 2016 to September 2021, ninety-seven uterine cervical/endometrial cancer patients received intensity-modulated radiation therapy were prospectively recruited in this single-arm, prospective, phase II trial.

MAD-Net: Multi-attention dense network for functional bone marrow segmentation.

Radiotherapy is the main treatment modality for various pelvic malignancies. However, high intensity radiation can damage the functional bone marrow (FBM), resulting in hematological toxicity (HT). Accurate identification and protection of the FBM during radiotherapy planning can reduce pelvic HT.